The present disclosure relates to skin closure devices applied over a surgical incision and preferably secured by a polymerizable adhesive, with the devices capable of forming drainage channels for removal of wound exudates.
A number of devices and methods exist for closing skin or tissue having a surgical incision, opening, cut, wound, or dissection. With these devices, skin or tissue parts separated by the incision are approximated or brought into close proximity forming as narrow a gap as possible in the area of the surgical incision or cut, and then covered by an adhesively attached tape which holds the skin or tissue in closed apposed arrangement until wound healing occurs after which the tape is removed.
Commercially available DERMABOND® PRINEO® Skin Closure System comprises a mesh having a pressure sensitive adhesive and a polymerization initiator disposed on the mesh. The mesh is applied onto the skin over a wound, and a polymerizable cyanoacrylate-based adhesive is then applied on the mesh and bonds the mesh to the skin.
However, skin closure systems may benefit from means to enable removal and drainage of wound exudates for wounds closed using skin closure systems, when required. Because skin closure systems seal the wound tightly, it can be beneficial to relieve any exudate pressure buildup or minimize the onset of skin maceration when the amount of exudates is significant.
U.S. Patent Application Publication No. 20140107561 “COMPRESSIVE OXYGEN DIFFUSIVE WOUND DRESSINGS” discloses a wound dressing, comprising: an oxygen-diffusive substrate defining a contact surface; and, a hydrophilic absorbent material in fluid communication with at least one portion of a periphery of the oxygen-diffusive substrate, wherein at least one portion of the substrate is configured to press the contact surface against a wound surface.
U.S. Patent Application Publication No. 20130274717 “SURGICAL CAVITY DRAINAGE AND CLOSURE SYSTEM” discloses a surgical drain device comprising a plurality of drain tubes positioned with an adhesion matrix, the adhesion matrix having a wound conforming shape and comprising a plurality of apertures for tissue contact through the matrix, the drain tubes being removable from the device and the adhesion matrix comprising a biodegradable polymer.
U.S. Patent Application Publication No. 20050085757 “EXPANDABLE TEMPORARY ABDOMINAL CLOSURE” discloses an abdominal and thoracic closure system comprising: a sterilizable flexible sheet comprising: a peripheral portion attachable to skin or fascia about a wound; and a central expandable portion allowing expansion of the abdomen or thorax while providing a continuous covering of a wound in the abdomen by the flexible sheet.
U.S. Patent Application Publication No. 20130066365 “RAPID CLOSING SURGICAL CLOSURE DEVICE” discloses a wound closure device, comprising: a first adhesion patch configured for adhering to a patient's skin; a second adhesion patch configured for adhering to the patient's skin; the wound closure device having an open position with an approximately elliptical shaped opening formed between the first adhesion patch and the second adhesion patch and a closed position wherein the first adhesion patch and the second adhesion patch are held in close proximity to each other.
U.S. Pat. No. 8,884,094 “VACUUM BANDAGE PACKING” discloses a vacuum bandage connectable to a source of fluid and provided for use with a wound having a wound surface, the bandage comprising: a wound dressing member having a wound contacting surface, a top surface, a port configured for fluid communication with the source of fluid, holes in the wound contacting surface configured for communication with a wound surface of the wound, and a passageway between the port and the holes, and a pack adjacent the top surface of the wound dressing member and having an aperture positioned about the port.
U.S. Pat. No. 9,381,284 “SYSTEM AND METHOD FOR SEALING AN INCISIONAL WOUND” discloses a method for treating an incisional wound having incisional walls, the method comprising: fluidly coupling a conduit to a source of reduced pressure, the conduit having a first end for receiving reduced pressure and a second end; fluidly coupling a scaffold to the second end of said conduit for receiving the reduced pressure, wherein the scaffold is formed from sufficiently thin porous material having an internal manifold extending generally longitudinally between opposing surfaces of the scaffold, the internal manifold having a primary flow channel comprised of bioresorbable tubing; positioning the opposing surfaces of the scaffold between the incisional walls of the incisional wound; fluidly coupling the internal manifold to the second end of the conduit for receiving the reduced pressure; surgically closing the incisional wound to maintain the reduced pressure therein; and providing the reduced pressure through the conduit to the scaffold and the internal manifold for the incisional wound, whereby the scaffold induces tissue apposition between the incisional walls.
U.S. Patent Application Publication No. 20100298791 “METHODS AND APPARATUSES FOR THE TREATMENT OF WOUNDS WITH PRESSURES ALTERED FROM ATMOSPHERIC” discloses an altered pressure device for treating a wound in an encapsulated space delimited by a cover secured over a wound, the device comprising: (a) an altered pressure source communicating with the encapsulated space via a length of tubing coupled with the source; and (b) layered intermediate materials composed of at least one foam layer and a top layer that is not foam, said non-foam layer in contact with the cover, wherein the top layer comprises structural characteristics that provide efficient gas permeation into the encapsulated space when interfacing with the cover.
Skin closure devices and dressings having porated or porous or apertured tape structure can release the pressure of wound exudates and provide for drainage, however these systems will also leave the incision and wound open to ingress of contaminates through the pores or apertures, potentially resulting in infection. There continues to be a need for improved devices, systems, and methods for holding skin areas around the dissection in apposed arrangement and covered and isolated from ingress of contaminants, while still providing for drainage of exudates.
In one embodiment, the invention relates to a device for application onto incisions or wounds with a liquid rapidly polymerizable adhesive for forming skin closure systems, comprising a thin flexible flat porous tape, preferably a mesh, elongated along a longitudinal axis and having a lower side or wound-facing side and an opposing upper side, a periphery, and central portion in immediate vicinity of the axis; said mesh coated or impregnated with an initiator or accelerator of polymerization; said mesh having a plurality of elongated traces of soluble pressure sensitive adhesive (PSA) disposed on the wound-facing side; said traces covering from about 3% to about 50% of area of said tape and extending from central portion to the periphery of said tape.
According to another embodiment, a method is provided of using the device for application onto incisions or wounds with a liquid rapidly polymerizable adhesive for forming skin closure systems on a wound for skin incision closure, comprising the steps: positioning a device comprising soluble PSA disposed on the wound-facing side of the device; orienting the axis of the device in alignment with the incision ensuring the axis is approximately overlapping the incision; approximating edges of the incision to each other with the device and adhering the device to the skin; applying a polymerizable adhesive onto the upper side of the tape, allowing the adhesive to penetrate through the tape and contact the skin; allowing the adhesive to react with the initiator or accelerator of polymerization and polymerize thus bonding the tape to the skin; allowing exudate from the wound to at least partially dissolve the traces of soluble pressure sensitive adhesive (PSA) thus forming drainage channels; providing coverage of the incision and keeping the incision closed.
According to embodiments of the present invention, self-forming drainage channels are provided to remove exudates and allow drainage from the wound or surgical incision towards the periphery of the skin closure system.
Referring now to
On lower side 23, which is the tissue or skin facing side of device 10, there is a plurality of elongated traces 30 of soluble pressure sensitive adhesive (PSA), said traces covering from 3% to about 50% of the area of tape 20, more preferably 5% to 40%, such as 5%, 10%, 20%, and extending from a central portion to periphery P of tape 20, the central portion being in the immediate vicinity of axis 21. Soluble PSA traces 30 and 32 are configured to form channels for drainage of exudates as will be discussed below.
Traces 30 originate close to axis 21 and terminate at periphery P. Traces 30 can be in a form of linear segments of soluble PSA and can run under any angle to axis 21. As shown in
As shown in
As shown in
As shown in
As shown in
In preferred embodiments, at least a portion of traces 30 and/or 32 overlaps axis 21.
Referring now to
PSA Reinforcing Zones
Referring now to
As shown in
As shown in
Referring now to
Optional PSA reinforcing zones 40, 45 may cover from 3% to about 50% of area of tape 20, more preferably 5% to 40%, such as 10%, 20%, 30%, 40%.
Soluble PSA traces 30 and 32 and optional PSA reinforcing zones 40, 45, in combination, may cover from about 5% to about 60% of area of mesh 20, more preferably 5% to 50%, such as 5%, 10%, 20%, 30%, 40%.
In Use
Referring now to
Optionally, tape 20 is used to approximate and hold in apposition or close approximation the edges of surgical incision or wound, using traces of soluble PSA 30, optional traces of soluble PSA 32, and/or optional traces of soluble or insoluble PSA 40, or insoluble PSA 45 for securing tape 20 on skin 100 and for securing in close approximation or apposition the edges of surgical incision or wound.
The positioning of device 10 over the surgical incision or wound is performed so that axis 21 is as much as possible aligned with the surgical incision or wound and overlaps with the surgical incision or wound i.e., axis 21 is in registration the surgical incision or wound.
As shown in
Liquid adhesive 50 then polymerizes and/or cross-links and solidifies, establishing secure bond with skin 100 and tape 20. Advantageously, areas where traces of soluble PSA 30 are present are free of adhesive 50 being in contact with skin and tape 20 and it is in these areas that skin 100 only is only attached by traces of soluble PSA 30. Skin closure by device 10 is thus completed with surgical incision under tape 20 securely covered and closed.
As shown in
Referring now to
Shielding Film Embodiments
Referring now to
In preferred embodiments, at least a portion of shielding film traces 70 overlap axis 21.
In one embodiment (not shown), elongated absorbent pads 60 are attached to at periphery P1 and P2 of tape 20. Absorbent pads 60 are configured to absorb exudate which are moving from the surgical incision or wound around axis 21 via drainage channels formed under shielding film traces 70 towards periphery P1 and P2.
Soluble PSA Traces
In some embodiments, soluble PSA traces 30, 32 are positioned in registration and alignment with non-soluble shielding film traces 70, 70a, with soluble PSA traces 30, 32 on lower side 23 immediately under corresponding shielding film traces 70, 70a on upper side 22 of tape 20. Shapes and arrangements of soluble PSA traces 30, 32 may be the same as shapes and arrangements of corresponding shielding film traces 70, 70a, with the same length but preferably with the width of shielding film traces 70, 70a being from 100% to 200% of the width of corresponding soluble PSA traces 30, 32, such as 100%, 120%, 150% of width of corresponding soluble PSA traces 30, 32.
PSA Reinforcing Zones
Embodiments of skin closure system device 10 are also disclosed whereby in addition to shielding film traces 70, 70a, there are provided additional and optional PSA reinforcing zones 40, 45, serving to improve attachment of device 10 to skin but not configured for forming drainage channels to remove exudate from central portions of device 10 around axis 21 to periphery P1, P2 of device 10. Similar in configurations to embodiments of
In Use
The embodiments of skin closure system device 10 of
As shown in
As shown in
In use, and referring to
Tape 20 is secured to skin by optional traces of soluble PSA 30, and also by optional traces of soluble PSA 32 (not shown), and also by optional traces of soluble or insoluble PSA 40 or insoluble PSA 45 (not shown).
Optionally, tape 20 is used to approximate and hold in apposition or close approximation the edges of surgical incision or wound, using traces of soluble PSA 30, optional traces of soluble PSA 32, and/or optional traces of soluble or insoluble PSA 40 or insoluble PSA 45 for securing tape 20 on skin 100 and for securing in close approximation or apposition the edges of surgical incision or wound.
The positioning of device 10 over the surgical incision or wound is performed so that axis 21 is as much as possible aligned with the surgical incision or wound and overlaps with the surgical incision or wound i.e., axis 21 is in registration the surgical incision or wound.
As shown in
Liquid adhesive 50 then polymerizes and/or cross-links and solidifies, establishing secure bond with skin 100 and mesh 20. Advantageously, areas where shielding film traces 70 are present are free of adhesive 50 being in contact with skin, with channels 30b forming under shielding film traces 70, creating narrow pathways or channels between skin 100 and tape 20 impregnated and covered with adhesive 50. Thus channels 30b are self-forming under shielding film traces 70. Channels 30b are narrow pathways between skin 100 and mesh 20 covered with adhesive 50, with channels 30b running under tape 20 and/or partially through tape 20.
As shown in
Liquid adhesive 50 then polymerizes and/or cross-links and solidifies, establishing secure bond with skin 100 and tape 20. Advantageously, areas where shielding film traces 70 and soluble PSA 30 are present are free of adhesive 50 being in contact with skin. Channels 30b are formed under shielding film traces 70 and upon dissolution of soluble PSA 30, as exudates forming at the site of surgical incision at least partially dissolve traces of soluble PSA 30, creating narrow pathways or channels between skin 100 and tape 20 impregnated and covered with adhesive 50. Thus channels 30b are self-forming under shielding film traces 70. Channels 30b are narrow pathways between skin 100 and tape 20 covered with adhesive 50, with channels 30b running under tape 20 and/or partially through tape 20.
Sizes/Dimensions
Tape 20 can be of any elongated shape to cover an articulating joint, such as elliptical, rectangular, and similar. Tape 20 can have ratio of length to width of about 1:2 to about 1:20, such as 1:5. The length of tape 20 is from about 10 cm to about 50 cm, such as 25 cm. The width of tape 20 is from 2 cm to 10 cm, such 3 cm, 5 cm.
Porosity of tape 20 is defined by size of pores or holes being from about 0.01 mm2 to about 4 mm2, more preferably 0.1 mm2 to 1 mm2. Percent of open area in tape 20, or ratio of area of holes to area of material surrounding holes is from about 95%-about 20%, more preferably 90%-40% constituting open area.
Elongated traces 30, 32 of soluble pressure sensitive adhesive (PSA) have width from about 0.5 mm to about 7 mm, more preferably 1 mm to 5 mm, such as 1, 1.5, 2, 3, 4 mm. The length of elongated traces 30 is from about 50% of the width of tape 20 to about 300% of the width of mesh 20, such as 10, 15, 20, 30, 40, 50, 60 mm. The length of elongated traces 32 is from about 50% to about 100% of the length of tape 20, such as 50, 100, 200, 300 mm.
PSA reinforcing zones 40, 45 can be linear, circular, elliptical curvilinear, etc. and having dimensions configured to fit between elongated traces 30, 32 of soluble pressure sensitive adhesive (PSA). Thickness or diameters of PSA reinforcing zones 40, 45 may range from 0.2 mm to 3 mm, such as 0.3, 0.4, 0.5, 1, 2 mm.
Non-soluble shielding film traces 70 have length similar to length of elongated traces 30, 32 of soluble pressure sensitive adhesive (PSA). The width of shielding film traces 70 may be equal or larger than the width of elongated traces 30, 32, such as 3 mm to about 10 mm, more preferably 3 mm to 6 mm, such as 3, 4, 5 mm.
PSA
Soluble PSA materials are exemplified by water soluble pressure sensitive adhesives, including Hydrocolloids; Homo-polymer Emulsion (PVA); Water-based Acrylic Adhesives; Polyurethane Dispersions PUDs; Poly ethylene glycol; Dextrin/Starch-Based Adhesives; N-vinyl caprolactam homopolymers; N-vinyl pyrrolidone copolymers; polyvinyl alcohol; cellulose ethers; methylcellulose; carboxymethylcellulose; polyvinylpyrrolidone; Polyvinyl Acetates.
Insoluble PSA materials are exemplified by water insoluble pressure sensitive adhesives, including Acrylic adhesives; Cyanoacrylate adhesives; Epoxy; Silicone based adhesives; and Urethane.
Initiator
In a preferred embodiment, initiators and/or accelerators or rate modifiers of adhesive polymerization or cross-linking can be releasably disposed on tape 20 or releasably incorporated into mesh 20. For example, one or more chemical substances may be dispersed in or on tape 20 such as being chemically bound, physically bound, coated, absorbed, or adsorbed to it.
For example, a polymerization initiator or accelerator or rate modifier may be loaded in or on tape 20 so that the initiator or rate modifier provides the desired initiation or rate modification effect to a subsequently applied polymerizable adhesive composition. The polymerization initiator or rate modifier may be immobilized in or on tape 20, so that the initiator or rate modifier does not become detached from tape 20 and its residues are dispersed in the resultant polymeric material. Alternatively, for example, the polymerization initiator or rate modifier may be initially attached to tape 20, but only in such a manner that it becomes mobilized or solubilized by a subsequently applied polymerizable adhesive composition and dispersed in the resultant polymeric material.
If desired, a combination of chemical substances may also be provided in or on tape 20, to provide multiple effects. For example, a first chemical species (such as a polymerization initiator or rate modifier) may be immobilized in or on tape 20, while a second, different chemical species (such as a bioactive material) may be detachably attached to tape 20. Other combinations of chemical species and resultant effects are also envisioned.
When present in or on tape 20, the chemical substances (i.e., polymerization initiator, rate modifier, and/or bioactive materials, or other additives), may be incorporated in or on tape 20 in any suitable manner. For example, the chemical substance may be added to tape 20 by contacting tape 20 with a solution, mixture, or the like including the chemical substances. The chemical substance may be added to tape 20, for example, by dipping, spraying, roll coating, gravure coating, brushing, vapor deposition, or the like. Alternatively, the chemical substance may be incorporated into or onto tape 20 during manufacture of tape 20, such as during molding.
The polymerization initiator or rate modifier loaded in or on tape 20 may provide a number of advantages for example, so as to provide faster polymerization time. The concentration of polymerization initiator or rate modifier may be increased to provide even faster polymerization time.
Because the polymerization initiator or rate modifier is loaded directly in or on tape 20, it is not necessary to mix the polymerizable adhesive composition with a polymerization initiator or rate modifier prior to application. This may allow a longer working time, where the polymerizable monomer composition may be more precisely and carefully applied over a longer period of time.
Such suitable initiators are known in the art and are described, for example, in U.S. Pat. Nos. 5,928,611 and 6,620,846, both incorporated herein by reference in their entireties, and U.S. Patent Application No. 2002/0037310, also incorporated herein by reference in its entirety. Quaternary ammonium chloride and bromide salts useful as polymerization initiators are particularly suitable. By way of example, quaternary ammonium salts such as domiphen bromide, butyrylcholine chloride, benzalkonium bromide, acetyl choline chloride, among others, may be used.
Benzalkonium or benzyltrialkyl ammonium halides such as benzyltrialkyl ammonium chloride may be used. When used, the benzalkonium halide may be benzalkonium halide in its unpurified state, which comprises a mixture of varying chain-length compounds, or it can be any suitable purified compound including those having a chain length of from about 12 to about 18 carbon atoms, including but not limited to C12, C13, C14, C15, C16, C17, and C18 compounds. By way of example, the initiator may be a quaternary ammonium chloride salt such as benzyltrialkyl ammonium chloride (BTAC).
Other initiators or accelerators may also be selected by one of ordinary skill in the art without undue experimentation. Such suitable initiators or accelerators may include, but are not limited to, detergent compositions; surfactants: e.g., nonionic surfactants such as polysorbate 20 (e.g., Tween20™ from ICI Americas), polysorbate 80 (e.g., Tween 80™ from ICI Americas) and poloxamers, cationic surfactants such as tetrabutylammonium bromide, anionic surfactants such as sodium tetradecyl sulfate, and amphoteric or zwitterionic surfactants such as dodecyldimethyl(3-sulfopropyl)ammonium hydroxide, inner salt; amines, imines and amides, such as imidazole, arginine and povidine; phosphines, phosphites and phosphonium salts, such as triphenylphosphine and triethyl phosphite; alcohols such as ethylene glycol, methyl gallate; tannins; inorganic bases and salts, such as sodium bisulfate, calcium sulfate and sodium silicate; sulfur compounds such as thiourea and polysulfides; polymeric cyclic ethers such as monensin, nonactin, crown ethers, calixarenes and polymeric-epoxides; cyclic and acyclic carbonates, such as diethyl carbonate; phase transfer catalysts such as Aliquat 336; organometallics such as cobalt naphthenate and manganese acetylacetonate; and radical initiators or accelerators and radicals, such as di-t-butyl peroxide and azobisisobutyronitrile.
Mixtures of two or more, such as three, four, or more, initiators or accelerators may be used. A combination of multiple initiators or accelerators may be beneficial, for example, to tailor the initiator of the polymerizable monomer species. For example, where a blend of monomers is used, a blend of initiators may provide superior results to a single initiator. For example, the blend of initiators can provide one initiator that preferentially initiates one monomer, and a second initiator that preferentially initiates the other monomer, or can provide initiation rates to help ensure that both monomer species are initiated at equivalent, or desired non-equivalent, rates. In this manner, a blend of initiators can help minimize the amount of initiator necessary. Furthermore, a blend of initiators may enhance the polymerization reaction kinetics.
Adhesive
In one embodiment, liquid or semi-liquid adhesive 50 is polymerized or is cross-linked polymerized or is cross-linked after coming in contact with initiators and/or accelerators of adhesive polymerization and/or cross-linking, including naturally found initiators on the tissue, such as moisture, traces of proteins, etc.
Such initiators and/or accelerators can be coated or disposed non-releasably, i.e. immobilized in or on the tape 20 while retaining activity to initiate or accelerate polymerization and/or cross-linking. In one embodiment, initiators and/or accelerators are disposed releasably, i.e., they can be at least partially released into and mix with flowing adhesive 50.
In a preferred embodiment, adhesive 50 is polymerized or is cross-linked after coming in contact with initiators and/or accelerators releasably disposed in or on tape 20. Rapid polymerization and/or crosslinking of adhesive 50 results in bonding of device 10 to tissue.
Adhesive 50 can be any type of biocompatible and rapidly cross-linkable and/or polymerizable compound or mixture of compounds. Rapidly cross-linkable and/or polymerizable means that after initiators or accelerators are added, or after the adhesive is formed from two or more components, it is capable of curing, i.e. cross-linking and/or polymerizing within 0.2 min to about 20 min, more preferably within 0.5 min to 10 min, such as 1, 2, 3, 5 min.
In one embodiment, adhesive 50 is formed prior to application onto tape 20, for instance by mixing two components contained in separate barrels or a two-barrel syringe, by passing these two components through a mixing tip. In this embodiment, there is no crosslinking initiator or accelerator disposed inside of mesh 20. In one embodiment, adhesive 50 is formed by mixing fibrinogen and thrombin together.
In one embodiment, adhesive 50 comprises fibrinogen, and crosslinking initiator or accelerator disposed inside of mesh 20 comprises thrombin.
In a preferred embodiment, the polymerizable adhesive composition may comprise a polymerizable monomeric adhesive. In embodiments, the polymerizable adhesive composition comprises a polymerizable 1,1-disubstituted ethylene monomer formulation. In embodiments, the polymerizable adhesive composition comprises a cyanoacrylate formulation. In embodiments, synthetic polymerizable adhesive materials such as polyurethane, polyethylene glycol, acrylates, glutaraldehyde and biologically based adhesives may be used.
Suitable .alpha.-cyanoacrylate monomers which may be used, alone or in combination, include alkyl .alpha.-cyanoacrylates such as 2-octyl cyanoacrylate; dodecyl cyanoacrylate; 2-ethylhexyl cyanoacrylate; butyl cyanoacrylate such as n-butyl cyanoacrylate; ethyl cyanoacrylate; methyl cyanoacrylate or other .alpha.-cyanoacrylate monomers such as methoxyethyl cyanoacrylate; 2-ethoxyethyl cyanoacrylate; 3-methoxybutyl cyanoacrylate; 2-butoxyethyl cyanoacrylate; 2-isopropoxyethyl cyanoacrylate; and 1-methoxy-2-propyl cyanoacrylate. In embodiments, the monomers are ethyl, n-butyl, or 2-octyl .alpha.-cyanoacrylate. Other cyanoacrylate monomers which may be used include alkyl ester cyanoacrylates, such as those prepared by the Knoevenagel reaction of an alkyl cyanoacetate, or an alkyl ester cyanoacetate, with paraformaldehyde, subsequent thermal cracking of the resultant oligomer and distillation.
Many other adhesive formulations can be used and are known to a skilled artisan. For example, mixtures containing PEG succinimidyl glutarate can be used as a flowable adhesive.
It should be understood that the foregoing disclosure and description of the embodiments of the present invention are illustrative and explanatory thereof and various changes in the size, shape and materials as well as in the description of the preferred embodiment may be made without departing from the spirit of the invention.
Number | Name | Date | Kind |
---|---|---|---|
167162 | French | Aug 1875 | A |
1656199 | Ensley | Jan 1928 | A |
2399545 | Davis | Apr 1946 | A |
2508855 | Brown | May 1950 | A |
2721858 | Joyner et al. | Oct 1955 | A |
2722220 | Mestrand | Nov 1955 | A |
2807262 | Lew | Sep 1957 | A |
2905174 | Smith | May 1959 | A |
3085572 | Blackford | Apr 1963 | A |
3254111 | Hawkins et al. | May 1966 | A |
3402716 | Baxter | Sep 1968 | A |
3520300 | Flower, Jr. | Jul 1970 | A |
3731683 | Zaffaroni | May 1973 | A |
3888247 | Stenvall | Jun 1975 | A |
3940362 | Overhults | Feb 1976 | A |
3983878 | Kawchitch | Oct 1976 | A |
3995641 | Kronenthal et al. | Dec 1976 | A |
4068664 | Sharp et al. | Jan 1978 | A |
4080348 | Korpman | Mar 1978 | A |
4126130 | Cowden et al. | Nov 1978 | A |
4140115 | Schonfeld | Feb 1979 | A |
4263906 | Finley | Apr 1981 | A |
4313865 | Teramoto et al. | Feb 1982 | A |
4340043 | Seymour | Jul 1982 | A |
4364876 | Kimura et al. | Dec 1982 | A |
4390519 | Sawyer | Jun 1983 | A |
4460369 | Seymour | Jul 1984 | A |
4560723 | Millet et al. | Dec 1985 | A |
4584355 | Blizzard et al. | Apr 1986 | A |
4585836 | Homan et al. | Apr 1986 | A |
4591622 | Blizzard et al. | May 1986 | A |
4612230 | Liland et al. | Sep 1986 | A |
4614183 | McCracken et al. | Sep 1986 | A |
4630603 | Greenway | Dec 1986 | A |
4655767 | Woodard et al. | Apr 1987 | A |
4671266 | Legnyel et al. | Jun 1987 | A |
4720513 | Kameyama et al. | Jan 1988 | A |
4728380 | Jones et al. | Mar 1988 | A |
4733659 | Edenbaum et al. | Mar 1988 | A |
4767401 | Seiderman | Aug 1988 | A |
4793887 | Card et al. | Dec 1988 | A |
4793888 | Card et al. | Dec 1988 | A |
4795435 | Steer et al. | Jan 1989 | A |
4852571 | Gadsby et al. | Aug 1989 | A |
4867747 | Yarger | Sep 1989 | A |
4872450 | Austad | Oct 1989 | A |
4950282 | Beisang et al. | Aug 1990 | A |
4966605 | Thieler | Oct 1990 | A |
4999235 | Lunn et al. | Mar 1991 | A |
5035687 | Sandbank | Jul 1991 | A |
5059424 | Cartmell et al. | Oct 1991 | A |
5086763 | Hathman | Feb 1992 | A |
5088483 | Heinecke | Feb 1992 | A |
5106362 | Gilman | Apr 1992 | A |
5125907 | Philpott | Jun 1992 | A |
5164444 | Bernard | Nov 1992 | A |
5173302 | Holmblad et al. | Dec 1992 | A |
5232958 | Mallya et al. | Aug 1993 | A |
5254132 | Barley et al. | Oct 1993 | A |
5259835 | Clark et al. | Nov 1993 | A |
5266371 | Sugii et al. | Nov 1993 | A |
D347059 | Mota | May 1994 | S |
5308313 | Karami et al. | May 1994 | A |
5328687 | Leung et al. | Jul 1994 | A |
5336209 | Porzilli | Aug 1994 | A |
5415626 | Goodman et al. | May 1995 | A |
5429592 | Jensen | Jul 1995 | A |
5445597 | Clark et al. | Aug 1995 | A |
5449340 | Tollini | Sep 1995 | A |
D363126 | Dusek | Oct 1995 | S |
5456660 | Reich et al. | Oct 1995 | A |
5476440 | Edenbaum | Dec 1995 | A |
5486547 | Matsuda et al. | Jan 1996 | A |
D370258 | Newman | May 1996 | S |
D373750 | Gunderson | Sep 1996 | S |
5571079 | Bello et al. | Nov 1996 | A |
5575997 | Leung et al. | Nov 1996 | A |
5582834 | Leung et al. | Dec 1996 | A |
5599858 | Buchanan et al. | Feb 1997 | A |
5620702 | Podell et al. | Apr 1997 | A |
5623011 | Bernard | Apr 1997 | A |
5624669 | Leung et al. | Apr 1997 | A |
D382343 | Wandell et al. | Aug 1997 | S |
5653769 | Barley, Jr. et al. | Aug 1997 | A |
D383211 | Dunshee et al. | Sep 1997 | S |
5662599 | Reich et al. | Sep 1997 | A |
D387169 | Dunshee et al. | Dec 1997 | S |
D389244 | Dunshee et al. | Jan 1998 | S |
5705551 | Sasaki et al. | Jan 1998 | A |
D391639 | Dunshee et al. | Mar 1998 | S |
5749895 | Sawyer et al. | May 1998 | A |
5762955 | Smith | Jun 1998 | A |
5780048 | Lee | Jul 1998 | A |
5782788 | Widemire | Jul 1998 | A |
5823983 | Rosofsky et al. | Oct 1998 | A |
5823986 | Peterson | Oct 1998 | A |
D402371 | Haynes et al. | Dec 1998 | S |
D403425 | Hinds et al. | Dec 1998 | S |
D404139 | Young | Jan 1999 | S |
5861348 | Kase | Jan 1999 | A |
5876745 | Muraoka et al. | Mar 1999 | A |
5902443 | Kanakubo et al. | May 1999 | A |
5928611 | Leung | Jul 1999 | A |
5931800 | Rasmussen et al. | Aug 1999 | A |
5947917 | Carté et al. | Sep 1999 | A |
5951505 | Gilman et al. | Sep 1999 | A |
5998694 | Jensen et al. | Dec 1999 | A |
D424699 | Allen | May 2000 | S |
6093465 | Gilchrist et al. | Jul 2000 | A |
6125265 | Yamamoto et al. | Sep 2000 | A |
6140548 | Hansen et al. | Oct 2000 | A |
6143352 | Clark et al. | Nov 2000 | A |
6155265 | Hammerslag | Dec 2000 | A |
6183593 | Narang et al. | Feb 2001 | B1 |
D439973 | Choksi | Apr 2001 | S |
6217603 | Clark et al. | Apr 2001 | B1 |
6238692 | Smith | May 2001 | B1 |
6245960 | Eaton | Jun 2001 | B1 |
6284941 | Cox et al. | Sep 2001 | B1 |
6310166 | Hickey et al. | Oct 2001 | B1 |
6329564 | Lebner | Dec 2001 | B1 |
6352704 | Nicholson et al. | Mar 2002 | B1 |
D458687 | Dale et al. | Jun 2002 | S |
6410818 | Oyaski | Jun 2002 | B1 |
6439789 | Balance et al. | Aug 2002 | B1 |
D463564 | Siegwart et al. | Sep 2002 | S |
6455064 | Narang et al. | Sep 2002 | B1 |
6479725 | Brothers | Nov 2002 | B1 |
6482431 | Smith | Nov 2002 | B2 |
6512023 | Malofsky et al. | Jan 2003 | B1 |
D471984 | Dunshee et al. | Mar 2003 | S |
D472319 | Oltmann | Mar 2003 | S |
6559350 | Tetreault et al. | May 2003 | B1 |
6579469 | Nicholson et al. | Jun 2003 | B1 |
6582713 | Newell et al. | Jun 2003 | B2 |
D477076 | Wall | Jul 2003 | S |
6589269 | Zhu et al. | Jul 2003 | B2 |
6595940 | D'Alessio et al. | Jul 2003 | B1 |
6596917 | Oyaski | Jul 2003 | B2 |
6599318 | Gabbay | Jul 2003 | B1 |
6620846 | Jonn et al. | Sep 2003 | B1 |
D480879 | Boehm et al. | Oct 2003 | S |
6632450 | Gregory | Oct 2003 | B1 |
6635272 | Leaderman | Oct 2003 | B2 |
6652559 | Tetreault et al. | Nov 2003 | B1 |
6667051 | Gregory | Dec 2003 | B1 |
6712839 | Lönne | Mar 2004 | B1 |
6787682 | Gilman | Sep 2004 | B2 |
6837027 | Hickey | Jan 2005 | B2 |
6841716 | Tsutsumi | Jan 2005 | B1 |
6942683 | Dunshee | Sep 2005 | B2 |
D515701 | Horhota et al. | Feb 2006 | S |
D516728 | Wall | Mar 2006 | S |
D520639 | Dodd et al. | May 2006 | S |
7041124 | Purcell | May 2006 | B2 |
7044982 | Milbocker | May 2006 | B2 |
7066934 | Kirsch | Jun 2006 | B2 |
7122712 | Lutri et al. | Oct 2006 | B2 |
7144390 | Hannigan et al. | Dec 2006 | B1 |
7164054 | Mori et al. | Jan 2007 | B2 |
D548348 | Nash | Aug 2007 | S |
7252837 | Guo et al. | Aug 2007 | B2 |
D562461 | Nash et al. | Feb 2008 | S |
7371400 | Borenstein et al. | May 2008 | B2 |
D574962 | Atkins et al. | Aug 2008 | S |
D580553 | Nash | Nov 2008 | S |
D581467 | Winningham et al. | Nov 2008 | S |
7457667 | Skiba | Nov 2008 | B2 |
D582561 | Sachi | Dec 2008 | S |
D584415 | Sachi | Jan 2009 | S |
7576257 | LaGreca, Sr. | Aug 2009 | B2 |
D611156 | Dunshee | Mar 2010 | S |
7713463 | Reah et al. | May 2010 | B1 |
D618810 | Tanigawa et al. | Jun 2010 | S |
D621052 | Kase | Aug 2010 | S |
D621053 | Kase | Aug 2010 | S |
D624190 | Neri | Sep 2010 | S |
D632398 | Bray et al. | Feb 2011 | S |
D636881 | Clemens et al. | Apr 2011 | S |
7943811 | Da Silva Macedo, Jr. | May 2011 | B2 |
7981136 | Weiser | Jul 2011 | B2 |
7982087 | Greener et al. | Jul 2011 | B2 |
D646789 | Barth | Oct 2011 | S |
8343606 | Marchitto et al. | Jan 2013 | B2 |
8353966 | Day et al. | Jan 2013 | B2 |
D676490 | Bratter et al. | Feb 2013 | S |
8372051 | Scholz et al. | Feb 2013 | B2 |
D679098 | Ogawa | Apr 2013 | S |
D679402 | Conrad-Vlasak et al. | Apr 2013 | S |
D679403 | Heinecke et al. | Apr 2013 | S |
D679405 | Arbesman | Apr 2013 | S |
D679819 | Peron | Apr 2013 | S |
D679820 | Peron | Apr 2013 | S |
D685484 | Brambilla | Jul 2013 | S |
8528730 | Grossman | Sep 2013 | B2 |
D691730 | Smith et al. | Oct 2013 | S |
D692566 | Adoni | Oct 2013 | S |
D693010 | Mosa et al. | Nov 2013 | S |
D694892 | Chan et al. | Dec 2013 | S |
8603053 | Riesinger | Dec 2013 | B2 |
D697216 | Chan et al. | Jan 2014 | S |
8642831 | Larsen et al. | Feb 2014 | B2 |
8663171 | Tambourgi et al. | Mar 2014 | B2 |
D705429 | Cheney et al. | May 2014 | S |
D707829 | Chan et al. | Jun 2014 | S |
D708751 | Chan et al. | Jul 2014 | S |
8777986 | Straehnz et al. | Jul 2014 | B2 |
D712045 | Thornton | Aug 2014 | S |
D713534 | Manley, Jr. | Sep 2014 | S |
D713967 | Adoni | Sep 2014 | S |
D714575 | Mah | Oct 2014 | S |
8884094 | Lockwood et al. | Nov 2014 | B2 |
D718812 | Sukhbaatar | Dec 2014 | S |
9000251 | Murphy et al. | Apr 2015 | B2 |
RE45510 | Hisamitsu | May 2015 | E |
D728803 | Sinda et al. | May 2015 | S |
D745688 | Chan et al. | Dec 2015 | S |
D745689 | Chan et al. | Dec 2015 | S |
D746479 | Arefieg | Dec 2015 | S |
RE45864 | Peron | Jan 2016 | E |
D746996 | Karlsson et al. | Jan 2016 | S |
D750789 | Mackay et al. | Mar 2016 | S |
D757950 | Karlsson et al. | May 2016 | S |
9339417 | Ogawa | May 2016 | B2 |
9381284 | Cornet et al. | Jul 2016 | B2 |
9440010 | Locke | Sep 2016 | B2 |
9492171 | Patenaude | Nov 2016 | B2 |
9623142 | Jonn et al. | Apr 2017 | B2 |
D786350 | Nakai et al. | May 2017 | S |
D786351 | Nakai et al. | May 2017 | S |
D786352 | Nakai et al. | May 2017 | S |
D786353 | Nakai et al. | May 2017 | S |
D786972 | Nakai et al. | May 2017 | S |
9655622 | Jonn et al. | May 2017 | B2 |
D790071 | Ahsani | Jun 2017 | S |
D824525 | Lacy et al. | Jul 2018 | S |
D833526 | Nakai et al. | Nov 2018 | S |
10434211 | Jonn et al. | Oct 2019 | B2 |
10470935 | Quintero | Nov 2019 | B2 |
20010002432 | Bugge | May 2001 | A1 |
20010028943 | Mashiko et al. | Oct 2001 | A1 |
20010037077 | Wiemken | Nov 2001 | A1 |
20020019652 | DaSilva et al. | Feb 2002 | A1 |
20020037310 | Jonn et al. | Mar 2002 | A1 |
20020039867 | Curro et al. | Apr 2002 | A1 |
20020185396 | Mainwaring et al. | Dec 2002 | A1 |
20020192107 | Hickey | Dec 2002 | A1 |
20020193721 | Vandruff | Dec 2002 | A1 |
20030031499 | Heard et al. | Feb 2003 | A1 |
20030093024 | Falleiros et al. | May 2003 | A1 |
20030100955 | Greenawalt et al. | May 2003 | A1 |
20030109819 | Tsuruda et al. | Jun 2003 | A1 |
20030125654 | Malik | Jul 2003 | A1 |
20030175824 | Pishko et al. | Sep 2003 | A1 |
20030220596 | Dunshee | Nov 2003 | A1 |
20030225355 | Butler | Dec 2003 | A1 |
20040001879 | Guo et al. | Jan 2004 | A1 |
20040060867 | Kriksunov et al. | Apr 2004 | A1 |
20040120849 | Stewart et al. | Jun 2004 | A1 |
20040142041 | MacDonald et al. | Jul 2004 | A1 |
20040162512 | Liedtke et al. | Aug 2004 | A1 |
20040220505 | Worthley | Nov 2004 | A1 |
20050015036 | Lutri et al. | Jan 2005 | A1 |
20050043820 | Browning | Feb 2005 | A1 |
20050085757 | Santanello | Apr 2005 | A1 |
20050147457 | Badejo et al. | Jul 2005 | A1 |
20050153090 | Marchitto et al. | Jul 2005 | A1 |
20050154340 | Schlussel | Jul 2005 | A1 |
20050182443 | Jonn | Aug 2005 | A1 |
20050208100 | Weber et al. | Sep 2005 | A1 |
20050288706 | Widomski et al. | Dec 2005 | A1 |
20060058721 | Lebner et al. | Mar 2006 | A1 |
20060141012 | Gingras | Jun 2006 | A1 |
20060173394 | Stroock et al. | Aug 2006 | A1 |
20060265005 | Beese | Nov 2006 | A1 |
20070106195 | Marcoux et al. | May 2007 | A1 |
20070218101 | Johnson et al. | Sep 2007 | A1 |
20070272211 | Kassner | Nov 2007 | A1 |
20070299542 | Mathisen et al. | Dec 2007 | A1 |
20080051687 | Rogers | Feb 2008 | A1 |
20080154168 | Lutri | Feb 2008 | A1 |
20080086113 | Tenney et al. | Apr 2008 | A1 |
20080109034 | Mather et al. | May 2008 | A1 |
20080110961 | Voegele et al. | May 2008 | A1 |
20080167633 | Vannucci | Jul 2008 | A1 |
20080280037 | Sheridan et al. | Nov 2008 | A1 |
20080302487 | Goodman et al. | Dec 2008 | A1 |
20090074842 | Hsu | Mar 2009 | A1 |
20100106120 | Holm | Apr 2010 | A1 |
20100198161 | Propp | Aug 2010 | A1 |
20100262091 | Larsson | Oct 2010 | A1 |
20100298791 | Jones et al. | Nov 2010 | A1 |
20110047766 | McAulay et al. | Mar 2011 | A1 |
20110071415 | Karwoski et al. | Mar 2011 | A1 |
20110092874 | Baschnagel | Apr 2011 | A1 |
20110130699 | Madsen et al. | Jun 2011 | A1 |
20110208102 | Chawki | Aug 2011 | A1 |
20110253303 | Miyachi et al. | Oct 2011 | A1 |
20120220912 | Shang | Aug 2012 | A1 |
20120238933 | Murphy et al. | Sep 2012 | A1 |
20120277645 | Kikuta et al. | Nov 2012 | A1 |
20130012988 | Blume et al. | Jan 2013 | A1 |
20130041337 | Aali et al. | Feb 2013 | A1 |
20130066365 | Belson et al. | Mar 2013 | A1 |
20130084323 | Riebman et al. | Apr 2013 | A1 |
20130138068 | Hu et al. | May 2013 | A1 |
20130143326 | Tai et al. | Jun 2013 | A1 |
20130144399 | Tai et al. | Jun 2013 | A1 |
20130204077 | Nagale et al. | Aug 2013 | A1 |
20130218125 | Stopek et al. | Aug 2013 | A1 |
20130245784 | Tan et al. | Sep 2013 | A1 |
20130274717 | Dunn | Oct 2013 | A1 |
20130282049 | Peterson et al. | Oct 2013 | A1 |
20130317405 | Ha et al. | Nov 2013 | A1 |
20140024989 | Ueda | Jan 2014 | A1 |
20140107561 | Dorian et al. | Apr 2014 | A1 |
20140121649 | Calco | May 2014 | A1 |
20140155916 | Hodgkinson et al. | Jun 2014 | A1 |
20140171888 | Croizat et al. | Jun 2014 | A1 |
20140257348 | Priewe et al. | Sep 2014 | A1 |
20140257517 | Deichmann et al. | Sep 2014 | A1 |
20150057491 | Goddard et al. | Feb 2015 | A1 |
20150209186 | Abbott et al. | Jul 2015 | A1 |
20150257938 | Pensier | Sep 2015 | A1 |
20150297413 | Blanco | Oct 2015 | A1 |
20150314114 | La Rosa | Nov 2015 | A1 |
20150351767 | Zoll et al. | Dec 2015 | A1 |
20160030248 | Potters | Feb 2016 | A1 |
20160045376 | Nielsen | Feb 2016 | A1 |
20160089145 | Quintero et al. | Mar 2016 | A1 |
20160296673 | Sambusseti | Oct 2016 | A1 |
20170035422 | Belson et al. | Feb 2017 | A1 |
20170056568 | Shelton, IV et al. | Mar 2017 | A1 |
20170056569 | Vendely et al. | Mar 2017 | A1 |
20170189159 | Bartee et al. | Jul 2017 | A1 |
20170273837 | Brueckner | Sep 2017 | A1 |
20170367806 | Gingras et al. | Dec 2017 | A1 |
20180085103 | Quintero et al. | Mar 2018 | A1 |
20180085259 | Quintero | Mar 2018 | A1 |
20180085260 | Quintero | Mar 2018 | A1 |
20190381207 | Jonn et al. | Dec 2019 | A1 |
Number | Date | Country |
---|---|---|
2262408 | Aug 2000 | CA |
1697639 | Nov 2005 | CN |
201441532 | Apr 2010 | CN |
101965169 | Feb 2011 | CN |
102755216 | Oct 2012 | CN |
102781433 | Nov 2012 | CN |
203234898 | Oct 2013 | CN |
204766892 | Nov 2015 | CN |
0532275 | Mar 1993 | EP |
0730874 | Sep 1996 | EP |
0746293 | Dec 1996 | EP |
1161212 | Aug 2000 | EP |
2359782 | Aug 2011 | EP |
2377498 | Oct 2011 | EP |
2805698 | Nov 2014 | EP |
3574875 | Dec 2019 | EP |
2078763 | Jan 1982 | GB |
61-203020 | Dec 1986 | JP |
62-87624 | Jun 1987 | JP |
01-265967 | Oct 1988 | JP |
2-140948 | Nov 1990 | JP |
3-56429 | May 1991 | JP |
7-016258 | Jan 1995 | JP |
2001-265967 | Sep 2001 | JP |
1130927 | Nov 2001 | JP |
2002-537068 | Nov 2002 | JP |
2003-153949 | May 2003 | JP |
2004-24905 | Jan 2004 | JP |
2006-061263 | Mar 2006 | JP |
3147394 | Dec 2008 | JP |
2009-022730 | Feb 2009 | JP |
1359502 | May 2009 | JP |
2011-004850 | Jan 2011 | JP |
1571238 | Mar 2017 | JP |
1629290 | Apr 2019 | JP |
WO 1983002586 | Aug 1983 | WO |
WO 1995004511 | Feb 1995 | WO |
WO 1996040797 | Dec 1996 | WO |
WO 1998026719 | Jun 1998 | WO |
WO 2000049983 | Aug 2000 | WO |
WO 2004049987 | Jun 2004 | WO |
2005007022 | Jan 2005 | WO |
WO 2005051259 | Jun 2005 | WO |
WO 2005079674 | Sep 2005 | WO |
WO 2006017109 | Feb 2006 | WO |
WO 2008082444 | Jul 2008 | WO |
WO 2009067062 | May 2009 | WO |
WO 2010134873 | Nov 2010 | WO |
2011152368 | Dec 2011 | WO |
WO 2013009725 | Jan 2013 | WO |
WO 2014083570 | Jun 2014 | WO |
WO 2014195710 | Dec 2014 | WO |
WO 2015135351 | Sep 2015 | WO |
Entry |
---|
3M™ Steri-Strip Adhesive Closures Product Catalog Brochure, (2011) 4 pages. |
3M™ Steri-Strip Adhesive Closures Product Catalog Brochure, (2011) 8 pages. |
3M™ Steri-Strip Adhesive Closures Product Catalog Brochure, (2012) 12 pages. |
Allen, L.V. Jr et al Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, 8th edition 2005 Lippincott Williams & Wilkins, Chapter 4, Dosage Form Design: Pharmaceutical and Formulation Considerations p. 131. |
Ashley et al.: Further studies involving wound closure with a rapidly polymerizing adhesive; Plastic and Reconstructive Surgery; Apr. 1963; vol. 31; pp. 333-343. |
Ashley et al.: Nonsutured closure of skin lacerations and nonsutured grafting of skin with a rapidly polymerizing adhesive; Qtrly Bull. Northwestern University (Evanston, III.) Medical School; 1962; vol. 36; pp. 189-194. |
Brombeg et al.: Nonsuture fixation of split-thickness skin grafts; Surgery, Jun. 1964; vol. 55; pp. 846-853. |
Cramer: Rapid Skin Grafting in Small Animals; Plastic and Reconstructive Surgery and the Transplantation Bull; Oct. 1962, vol. 30; pp. 149-150. |
Cramer et al.: Autograft rejection induced by homografting. A phenomenon intermediate between homograft rejection and autoimmunity; Plastic and Reconstructive Surgery; Jun. 1965; vol. 35; pp. 572-587. |
DeMaria, E. ‘New skin closure system facilitates wound healing after cardiovascular implantable electronic device surgery’ World Journal of Clinical Cases (2015) 3(8) pp. 675-677. |
Dermabond Prineo Skin Closure Systems (22 cm) Brochure (2014), 7 pages. |
Dermabond Prineo Skin Closure Systems (22 cm) Brochure (2015), 2 pages. |
Healthcare Packaging. Advanced Wound Care Products and packaging Needs. Jun. 5, 2017 (earliest online date), [site visited May 8, 2018]. Available from the Internet, URL:https://www.healthcarepackaging.com/article/applications/healthcare/advanced-wound-care-products-and-packaging-needs> (Year: 2017). |
Inou: Studies on the Surgical Use of Plastic Adhesive; Am. Journal of Proctology; 1962; vol. 13; pp. 219-226. |
Jesse et al.: Fixation of split-thickness skin grafts with adhesive; Plastic and Reconstructive Surgery; Mar. 1964; vol. 33; pp. 272-277. |
Kaplan: A technique of nonsuture wound closure with a plastic tissue adhesive; Plastic and Reconstructive Surgery; Feb. 1966; vol. 37(2); pp. 139-142. |
Keddie et al.: Intrafollicular tinea versicolor demonstrated on monomer plastic strips; Journal of Investigative Dermatology; Sep. 1963; vol. 41; pp. 103-106. |
Lazar, H.L. et al ‘Novel Adhesive Skin Closures Improve Wound Healing Following Saphenous Vein Harvesting’ J. Card Surg (2008) 23 pp. 152-155. |
Leukosan SkinLink Application Guide (2006) 1 page. |
Leukosan Skinlink. BSN Medical (2017) 1 page http://www.bsnmedical.com/products/wound%E2%80%90care%E2%80%90vascular/category%E2%80%90product%E2%80%90search/acute%E2%80%90wound%E2%80%90care/wound%E2%80%90closure/leukosanr%E2%80%90skinlink.html. |
Pam Marketing Nut. Yikes! The Social Medica Quick Fix Band-Aids are Falling Off! Jul. 2012 [earliest online date], [site visited May 8, 2018]. Available from Internet, ,URL:http://www.pammarketingnut.com/2012/07/yikes-the-social-media-quick-fix-band-aids-are-falling-off/> (Year: 2012). |
Parrish et al.: Synthetic resin adhesive for placement of skin grafts; American Surgeon; Nov. 1964; vol. 30; pp. 753-755. |
Raekallio et al.: Acute reaction to arterial adhesive in healing skin wounds; Journal of Surgical Research; Mar. 1964; vol. 4; pp. 124-127. |
Stone: Nonsuture closure of cutaneous lacerations, skin grafting and bowel anastomosis; American Surgeon; Mar. 1964; vol. 30; pp. 177-181. |
TissuGlu Surgical Adhesive Patient Information Brochure. Cohera Medical, Inc. (2014) 6 pages. |
TissuGlu FDA Summary of Safety and Effectiveness Data. Feb. 3, 2014 40 pages. |
Topaz, M. et al ‘The TopClosure 3S System, for skin stretching and a secure wound closure’ Eur J Plast Surg (2012) 35 pp. 533-543. |
TopClosure 3S System—Skin Stretching and Secure Wound Closure System Product Information Sheet (2010) 15 pages. |
Wolfe et al.: The application of hydrostatic pressure to the burn injury, an experimental study: Journal of Trauma: Injury Infections & critical Care; May 1962; vol. 2; pp. 262-272. |
ZipLine medical Zip Surgical Skin Closure Brochure (2013) 4 pages. |
Communication received from the USPTO for co-pending U.S. Appl. No. 10/887,884 dated Aug. 11, 2006. |
Communication received from USPTO for co-pending U.S. Appl. No. 10/779,721 dated Mar. 28, 2007. |
Communication received from USPTO for co-pending U.S. Appl. No. 10/779,721 dated Apr. 16, 2007. |
Communication received from the USPTO for co-pending U.S. Appl. No. 10/887,884 dated Mar. 6, 2008. |
Communication received from the USPTO for co-pending U.S. Appl. No. 10/887,884 dated Dec. 12, 2008. |
Communication received from the USPTO for co-pending U.S. Appl. No. 12/207,984 dated May 11, 2011. |
Communication received from the USPTO for co-pending U.S. Appl. No. 12/163,021 dated May 13, 2011. |
Communication received from the USPTO for co-pending U.S. Appl. No. 12/163,021 dated Feb. 2, 2012. |
Communication received from the USPTO for co-pending U.S. Appl. No. 12/163,021 dated Jun. 22, 2012. |
Communication received from the USPTO for co-pending U.S. Appl. No. 12/207,984 dated Jun. 28, 2012. |
Communication received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated Jun. 22, 2012. |
Corrected International Search Report International Application No. PCT/US2005/004948 dated Jun. 22, 2005. |
Extended European Search Report re: 14166813.7 dated Jul. 7, 2014. |
In re the U.S. Appl. No. 12/163,021 the Non-Final rejection dated Aug. 14, 2013. |
In re the U.S. Appl. No. 12/163,021 the Final rejection dated Jan. 3, 2014. |
In re the U.S. Appl. No. 12/207,984 the Non-Final rejection dated Aug. 22, 2013. |
In re the U.S. Appl. No. 12/207,984 the Final rejection dated Dec. 4, 2013. |
International Preliminary Report on Patentability for International Application No. PCT/US2005/024042 dated Jan. 16, 2007. |
International Search Report for International Application No. PCT/US2005/024042 dated May 12, 2006. |
International Search Report for International Application No. PCT/US2005/004948 dated Jun. 9, 2009. |
International Search Report re: PCT/US2015/051919 dated Apr. 14, 2016. |
International Search Report re: PCT/US2017/052394 dated Nov. 21, 2017. |
International Search Report re: PCT/US2017/052383 dated Dec. 6, 2017. |
International Search Report re PCT/US2018/022842 dated Jun. 20, 2018. |
International Search Report re PCT/US2018/022834 dated Jun. 22, 2018. |
International Search Report re PCT/US2018/027790 dated Jun. 26, 2018. |
Office action received from USPTO for co-pending U.S. Appl. No. 10/887,884 dated Apr. 25, 2006. |
Office action received from USPTO for co-pending U.S. Appl. No. 10/779,721 dated Aug. 21, 2006. |
Office action received from USPTO for co-pending U.S. Appl. No. 10/887,884 dated Oct. 12, 2006. |
Office action received from USPTO for co-pending U.S. Appl. No. 10/779,721 dated Jan. 9, 2007. |
Office Communication received from USPTO for co-pending U.S. Appl. No. 10/887,884 dated Jan. 22, 2007. |
Office Action received from USPTO for co-pending U.S. Appl. No. 10/887,884 dated Feb. 1, 2007. |
Office Action received from the USPTO for co-pending U.S. Appl. No. 12/163,021. |
Office action received from USPTO for co-pending U.S. Appl. No. 10/779,721 dated Jul. 27, 2007. |
Office Action received from USPTO for co-pending U.S. Appl. No. 10/887,884 dated Oct. 16, 2007. |
Office Action received from USPTO for co-pending U.S. Appl. No. 10/887,884 dated Mar. 6, 2008. |
Office action received from USPTO for co-pending U.S. Appl. No. 10/779,721 dated May 19, 2008. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated Jan. 9, 2010. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated Sep. 1, 2010. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/207,984 dated Sep. 1, 2010. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated Dec. 9, 2010. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/207,984 dated Dec. 9, 2010. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated May 13, 2011. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated Jul. 18, 2011. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/207,984 dated Aug. 1, 2011. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated Jan. 10, 2012. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/207,984 dated Jan. 17, 2012. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/207,984 dated Apr. 26, 2012. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated May 1, 2012. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated Sep. 17, 2012. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/207,984 dated Sep. 25, 2012. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated Aug. 14, 2013. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/207,984 dated Aug. 22, 2013. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/207,984 dated Dec. 4, 2013. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated Jan. 3, 2014. |
Supplementary European Search Report for Application No. EP05769387 dated Jul. 9, 2009. |
Supplementary European Search Report for Application No. EP05723162 dated Nov. 5, 2009. |
Supplementary European Search Report for Application No. EP14166813 dated Jun. 30, 2014. |
U.S. Appl. No. 09/430,177, filed Oct. 29, 1999. |
U.S. Appl. No. 09/430,289, filed Oct. 29, 1999. |
U.S. Appl. No. 09/430,180, filed Oct. 29, 1999. |
U.S. Appl. No. 09/385,030, filed Aug. 30, 1999. |
U.S. Appl. No. 09/176,889, filed Oct. 22, 1998. |
U.S. Appl. No. 09/919,877, filed Aug. 2, 2001. |
U.S. Appl. No. 10/779,721, filed Feb. 18, 2004. |
Written Opinion re: PCT/US2015/051919 dated Apr. 14, 2016. |
Written Opinion re: PCT/US2017/052394 dated Nov. 21, 2017. |
Written Opinion re: PCT/US2017/052383 dated Dec. 6, 2017. |
Written Opinion re: PCT/US2018/022842 dated Jun. 20, 2018. |
Written Opinion re: PCT/US2018/027790 dated Jun. 26, 2018. |
Written Opinion re PCT/US2018/022834 dated Jun. 22, 2018. |
Dermabond Prineo Skin Closure System (22 cm) Fact Sheet. (2016) 2 pages. |
JP 7040744,1995, English claims. |
JP 3059327,1991, English claims. |
Japanese Office Action dated Feb. 19, 2019 for Design Appln. No. 2018-017274. |
Japanese Office Action dated Feb. 26, 2019 for Patent Appln. No. 515463. |
Office action received from USPTO for U.S. Appl. No. 15/964,538 dated Oct. 25, 2018. |
Office action received from USPTO for U.S. Appl. No. 15/964,538 dated Dec. 27, 2018. |
Office action received from USPTO for U.S. Appl. No. 15/490,176 dated Feb. 4, 2019. |
Office action received from USPTO for U.S. Appl. No. 15/452,126 dated Nov. 16, 2018. |
Office action received from USPTO for U.S. Appl. No. 14/864,033 dated Nov. 26, 2018. |
Office action received from USPTO for U.S. Appl. No. 15/467,239 dated Feb. 28, 2019. |
Office action received from USPTO for U.S. Appl. No. 15/278,376 dated Sep. 11, 2018. |
Office action received from USPTO for U.S. Appl. No. 15/278,376 dated Feb. 21, 2019. |
Office action received from USPTO for U.S. Appl. No. 15/675,159 dated May 14, 2019. |
N/A, “Scar nose & Rinoplasty Surgery—New Gel+Demo:Nose Silicone Gel Sheet (beige)www.newgelplus.com”, www.youtube.com, 2012, pp. 1-3, Page Number. |
N/A, “Silagen Silicone Sheeting Strips Review|the skin spot”, www.youtube.com, 2017, pp. 1-3, Page Number. |
Number | Date | Country | |
---|---|---|---|
20180303967 A1 | Oct 2018 | US |